Ebola Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Emergent Risk Group-4 (RG-4) Filoviruses: A paradox in progress
Bioinformation. 2023 Aug 31;19(8):829-832. doi: 10.6026/97320630019829. eCollection 2023.ABSTRACTFiloviruses, categorized as World Health Organization (WHO) Risk Group 4 (RG-4) pathogens, represent significant global health risks due to their extraordinary virulence. The Filoviridae family encompasses Ebola strains such as Sudan, Zaire, Bundibugyo, Tai Forest (formerly known as Ivory Coast), Reston, and Bombali, in addition to the closely related Marburg and Ravn virus strains. Filoviruses originated from a common ancestor about 10,000 years ago and displayed remarkable consistency in genetic heterogeneity until the 20th c...
Source: Bioinformation - November 1, 2023 Category: Bioinformatics Authors: John T Sinnott Kami Kim Charurut Somboonwit Conor Cosnett David Segal Paul Shapshak Source Type: research

Ebola virus disease in children: epidemiology, pathogenesis, management, and prevention
Pediatr Res. 2023 Oct 30. doi: 10.1038/s41390-023-02873-y. Online ahead of print.ABSTRACTEbola disease is a severe disease with extremely high case-fatality rates ranging from 28-100%. Observations made during the 2013-2016 West African epidemic improved our understanding of the clinical course of Ebola disease and accelerated the study of therapeutic and preventative strategies. The epidemic also highlighted the unique challenges associated with providing optimal care for children during Ebola disease outbreaks. In this review, we outline current understanding of Ebola disease epidemiology, pathogenesis, management, and p...
Source: Pediatric Research - October 31, 2023 Category: Pediatrics Authors: Katherine R Dobbs Alyssa Lobb Arlene E Dent Source Type: research

The inclusion of pregnant women in vaccine clinical trials: An overview of late-stage clinical trials' records between 2018 and 2023
This study can inform future demands for increased inclusion, especially in industry-sponsored trials, as it provides an overview of the current vaccine trials scene.PMID:37903681 | DOI:10.1016/j.vaccine.2023.10.057 (Source: Vaccine)
Source: Vaccine - October 30, 2023 Category: Allergy & Immunology Authors: Maha Salloum Antea Paviotti Hilde Bastiaens Jean-Pierre Van Geertruyden Source Type: research

Stillbirths and neonatal deaths: a neglected global pandemic
Introduction The SARS-CoV-2 pandemic has attracted unprecedented attention within the global health (GH) community, the public and in politics worldwide, overshadowing numerous, long-existing major threats to GH (box 1). While resembling several other pandemics, it is perceived and portrayed as an ultimate threat to GH and security. This view is promoted mainly by high-income countries (HICs),1 but ignores the long-existing challenges especially those affecting children, namely climate change, poverty and hunger.2 3 Box 1Major threats to global health* Climate change, environmental degradation, exploitation of natural reso...
Source: Archives of Disease in Childhood - October 30, 2023 Category: Pediatrics Authors: Krüger, C. Tags: COVID-19 Viewpoint Source Type: research

BSL-4 facility and New virus research in Japan
Uirusu. 2022;72(1):1-6. doi: 10.2222/jsv.72.1.ABSTRACTViral hemorrhagic fevers such as Ebola virus disease, Marburg disease, Lassa fever, and Crimean-Congo hemorrhagic fever are infectious diseases that can cause severe, life-threatening illness. At present, there are only few licensed vaccines and antiviral drugs for these viral hemorrhagic fevers. The viruses which cause these viral hemorrhagic fevers are classified as BSL-4 pathogens and can be handled only in BSL-4 containment laboratories. Therefore, to develop the vaccines and treatments for these diseases, BSL-4 facility is essential. However, the BSL-4 facility ava...
Source: Uirusu. Journal of Virology - October 29, 2023 Category: Virology Authors: Jiro Yasuda Source Type: research